Kane Biotech Inc.
KNE.VTSXVHealthcare● Active
$0.03
+$0.01(+16.67%)
Market Cap$5455710
P/E Ratio—
52W High$0.07
52W Low$0.03
Kane Biotech Inc. (KNE.V) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KNE.V · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.43M | $2.08M | $0.15M | $0.16M | $1.61M |
| Cost of Revenue | $0.59M | $1.21M | $0.04M | $1.26M | $1.04M |
| Gross Profit | ($0.16M) | $0.87M | $0.11M | $1.41M | $0.57M |
| Gross Margin %(computed) | -38.18% | 41.91% | 73.48% | 901.68% | 35.36% |
| Operating Expenses | |||||
| R&D Expenses | $0.87M | $1.95M | $1.29M | $1.05M | $1.38M |
| G&A Expenses | $0.00M | $3.08M | $2.41M | $3.72M | $4.07M |
| Total Operating Expenses | $2.95M | $4.80M | $3.47M | $4.78M | $5.45M |
| Operating Income | ($3.11M) | ($4.49M) | ($3.36M) | ($3.46M) | ($4.88M) |
| Operating Margin %(computed) | -727.40% | -215.96% | — | — | -303.75% |
| Interest Income | $0.02M | $0.00M | $0.01M | $0.02M | $0.12M |
| Interest Expense | $0.24M | $0.55M | $1.22M | $0.82M | $0.42M |
| Income Before Tax | ($2.83M) | ($4.47M) | ($4.56M) | ($4.02M) | ($4.85M) |
| Income Tax Expense | ($0.11M) | ($1.31M) | $0.00M | $0.00M | $0.00M |
| Net Income | ($2.72M) | ($3.02M) | ($5.03M) | ($3.89M) | ($4.60M) |
| Net Margin %(computed) | -636.00% | -145.35% | — | — | -286.39% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.02 | $-0.02 | $-0.04 | $-0.03 | $-0.04 |
| Wtd Avg Shares | 162.22M | 133.91M | 140.26M | 120.70M | 112.60M |
| EBITDA | ($2.95M) | ($3.71M) | ($3.23M) | ($2.95M) | ($4.25M) |
| EBITDA Margin %(computed) | -689.37% | -178.17% | — | — | -264.08% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CAD · M
Explore more Kane Biotech Inc. data
About Kane Biotech Inc. (KNE.V) Income Statement
Kane Biotech Inc. (KNE.V) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KNE.V reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -38.18%), and net income of ($0.00B) — a net profit margin of -636.00%.
Frequently asked questions
KNE.V · 4 questionsKane Biotech Inc. (KNE.V) reported revenue of $0.00B for 2025, down 79.4% year-over-year.
KNE.V revenueKNE.V salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08